Premium
The Effects of Simultaneous Administration of Dietary Conjugated Linoleic Acid and Telmisartan on Cardiovascular Risks in Rats
Author(s) -
Abdullah Mohammad M.,
Xu Zuyuan,
Pierce Grant N.,
Moghadasian Mohammed H.
Publication year - 2007
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/s11745-007-3096-7
Subject(s) - telmisartan , medicine , conjugated linoleic acid , blood pressure , endocrinology , blood lipids , clinical chemistry , insulin , lipid profile , diabetes mellitus , metabolic syndrome , pharmacology , losartan , lipidology , cholesterol , linoleic acid , fatty acid , chemistry , angiotensin ii , biochemistry
Dietary conjugated linoleic acid (CLA) and the antihypertensive drug, telmisartan, have both been shown to modify cardiovascular risks. The effects of a combination of these two agents have, however, not been investigated. This 20 week study sought to assess the therapeutic potential of a CLA/telmisartan co‐administration in rats fed a high‐fructose high‐fat diet. Thirty‐three male Sprague–Dawley rats were randomly assigned to five experimental groups, including control, losartan, telmisartan, CLA, and CLA + telmisartan‐treated animals. Body weight, blood pressure, and blood levels of lipids, glucose, insulin, and inflammatory markers were measured. Co‐administration of CLA and telmisartan resulted in significant ( P < 0.05) reductions in body weight, visceral fat, serum total cholesterol, triglycerides, glucose, plasma insulin concentrations, and systolic blood pressure compared with those in the control group. Moreover, plasma levels of IL1‐α and IFN‐γ were reduced and levels of IL1‐β, IL‐4, IL‐6, and IL‐10, plus TNF‐α were increased in the co‐therapy group, compared with controls. In conclusion, this study suggests that a combination of CLA with telmisartan may modify several risk factors of cardiovascular disease commonly seen in metabolic syndrome. This combination of nutraceuticals and pharmaceuticals may be a safe and cost‐effective strategy in a number of high‐risk subjects. Future studies will further document clinical benefits of such combination therapy.